33
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Discovery of novel pyrazole-containing benzamides as potent RORγ inverse agonists.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The nuclear receptor RORγ plays a central role in controlling a pro-inflammatory gene expression program in several lymphocyte lineages including TH17 cells. RORγ-dependent inflammation has been implicated in the pathogenesis of several major autoimmune diseases and thus RORγ is an attractive target for therapeutic intervention in these diseases. Starting from a lead biaryl compound 4a, replacement of the head phenyl moiety with a substituted aminopyrazole group resulted in a series with improved physical properties. Further SAR exploration led to analogues (e.g., 4j and 5m) as potent RORγ inverse agonists.

          Related collections

          Author and article information

          Journal
          Bioorg. Med. Chem. Lett.
          Bioorganic & medicinal chemistry letters
          Elsevier BV
          1464-3405
          0960-894X
          Aug 01 2015
          : 25
          : 15
          Affiliations
          [1 ] Chemistry and Molecular Therapeutics, Biogen, 12 Cambridge Center, Cambridge, MA 02142, USA. Electronic address: taowang2@gmail.com.
          [2 ] Immunology Discovery, Biogen, 12 Cambridge Center, Cambridge, MA 02142, USA.
          [3 ] Chemistry and Molecular Therapeutics, Biogen, 12 Cambridge Center, Cambridge, MA 02142, USA.
          Article
          S0960-894X(15)00478-3
          10.1016/j.bmcl.2015.05.028
          26048789
          ff6f55d4-93e9-4617-8fde-ba8ba8744ee4
          History

          IL-17,RORγ inverse agonist,Th17 cell,Autoimmune disease,Inflammation

          Comments

          Comment on this article